A nuanced approach, rather than a knee-jerk reaction, is needed in deciding whether to pull an accelerated approval drug with a failed confirmatory trial. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
